Optimizing cholesterol treatment in patients with muscle complaints

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081 · see citing works

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins

(2005) · The Lancet · doi:10.1016/s0140-6736(05)67394-1 · Cited by 6,848 · see citing works

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487 · see citing works

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.002 · Cited by 3,845 · see citing works

ESC/EAS Guidelines for the management of dyslipidaemias

Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549 · see citing works

Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy

The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911 · see citing works

Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus

(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837 · cited 1× · see citing works

<i>SLCO1B1</i> Variants and Statin-Induced Myopathy — A Genomewide Study

(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801936 · Cited by 2,043 · see citing works

Interpretation of the evidence for the efficacy and safety of statin therapy

Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L., Blumenthal, R., Danesh, J., Smith, G. D., DeMets, D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31357-5 · Cited by 1,857 · see citing works

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

Canner, P. L., Berge, K. G., Wenger, N. K., Stamler, J., Friedman, L., Prineas, R. J., & Friedewald, W. (1986) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(86)80293-5 · Cited by 1,824 · see citing works

Effects of extended-release niacin with laropiprant in high-risk patients

The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668 · see citing works

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias

Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582 · see citing works

Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

Stroes, E. S., Thompson, P. D., Corsini, A., Vladutiu, G. D., Raal, F. J., Ray, K. K., Roden, M., Stein, E., Tokgözoğlu, L., Nordestgaard, B. G., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv043 · Cited by 1,443 · see citing works

Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study

Bruckert, E., Hayem, G., Dejager, S., Yau, C., & Bégaud, B. (2005) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-005-5686-z · Cited by 1,226 · see citing works

Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update

Schächter, M. (2004) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2004.00299.x · Cited by 1,216 · see citing works

Discontinuation of Statins in Routine Care Settings: A Cohort Study

Zhang, H., Plutzky, J., Skentzos, S., Morrison, F., Mar, P., Shubina, M., & Turchin, A. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-7-201304020-00004 · Cited by 548 · see citing works

Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance

Stroes, E., Colquhoun, D., Sullivan, D., Civeira, F., Rosenson, R. S., Watts, G. F., Bruckert, E., Cho, L., Dent, R., Knusel, B., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.03.019 · Cited by 526 · see citing works

Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial

Nissen, S. E., Stroes, E., Dent-Acosta, R. E., Rosenson, R. S., Lehman, S. J., Sattar, N., Preiss, D., Bruckert, E., Ceška, R., Lepor, N., et al. (2016) · JAMA · doi:10.1001/jama.2016.3608 · Cited by 522 · see citing works

Effect of statins on skeletal muscle function

Parker, B. A., Capizzi, J. A., Grimaldi, A. S., Clarkson, P. M., Cole, S. M., Keadle, J., Chipkin, S., Pescatello, L. S., Simpson, K., White, C. M., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.136101 · Cited by 500 · see citing works

The SLCO1B1*5Genetic Variant Is Associated With Statin-Induced Side Effects

Voora, D., Shah, S. H., Spasojević, I., Ali, S. Y., Reed, C. R., Salisbury, B. A., & Ginsburg, G. S. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.04.053 · Cited by 498 · see citing works

Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis

Pinkosky, S. L., Newton, R. S., Day, E. A., Ford, R. J., Lhotak, S., Austin, R. C., Birch, C. M., Smith, B. K., Filippov, S., Groot, P. H. E., et al. (2016) · Nature Communications · doi:10.1038/ncomms13457 · Cited by 498 · see citing works

Understanding statin use in America and gaps in patient education (USAGE): an internet-based survey of 10,138 current and former statin users

Cohen, J. D., Brinton, E. A., Ito, M. K., & Jacobson, T. A. (2012) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2012.03.003 · Cited by 486 · see citing works

An assessment by the statin muscle safety task force: 2014 update

Rosenson, R. S., Baker, S. K., Jacobson, T. A., Kopecky, S. L., & Parker, B. A. (2014) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2014.03.004 · Cited by 485 · see citing works

2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk

Lloyd-Jones, D. M., Morris, P. B., Ballantyne, C. M., Birtcher, K. K., Daly, D. D., DePalma, S. M., Minissian, M. B., Orringer, C. E., & Smith, S. C. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.519 · Cited by 459 · see citing works

Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients: The GAUSS Randomized Trial

Sullivan, D., Olsson, A. G., Scott, R., Kim, J. B., Xue, A., Gebski, V., Wasserman, S. M., & Stein, E. A. (2012) · JAMA · doi:10.1001/jama.2012.25790 · Cited by 447 · see citing works

Position paper Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel

Banach, M., Rizzo, M., Toth, P. P., Farnier, M., Davidson, M. H., Al‐Rasadi, K., Aronow, W. S., Athyros, V. G., Djuric, D. M., Владиславович, Е. М., et al. (2015) · Archives of Medical Science · doi:10.5114/aoms.2015.49807 · Cited by 381 · see citing works

Statin-Associated Autoimmune Myopathy

Mammen, A. L. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1515161 · Cited by 366 · see citing works

Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase

Gupta, A., Thompson, D., Whitehouse, A., Collier, T., Dahlof, B., Poulter, N., Collins, R., & Sever, P. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31075-9 · Cited by 343 · see citing works

Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association

Wiggins, B. S., Saseen, J. J., Page, R. L., II, Reed, B. N., Sneed, K., Kostis, J. B., Lanfear, D. E., Virani, S. S., & Morris, P. B. (2016) · Circulation · doi:10.1161/cir.0000000000000456 · Cited by 339 · see citing works

Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction

Serban, M.-C., Colantonio, L. D., Manthripragada, A. D., Monda, K. L., Bittner, V. A., Banach, M., Chen, L., Huang, L., Dent, R., Kent, S. T., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.12.036 · Cited by 318 · see citing works

Red Yeast Rice for Dyslipidemia in Statin-Intolerant Patients: A Randomized Trial

Becker, D. J., Gordon, R. Y., Halbert, S. C., French, B., Morris, P. B., & Rader, D. J. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-12-200906160-00006 · Cited by 275 · see citing works

A systematic review of statin-induced muscle problems in clinical trials

Ganga, H. V., Slim, H. B., & Thompson, P. D. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.03.019 · Cited by 253 · see citing works

Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016)

Mancini, G. B. J., Baker, S. K., Bergeron, J., FITCHETT, D. H., Frohlich, J. J., Genest, J. J., Gupta, M., Hegele, R. A., Ng, D. S., Pearson, G. J., et al. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.01.003 · Cited by 253 · see citing works

Combination lipid therapy in type 2 diabetes

(2010) · New England Journal of Medicine · doi:10.1056/nejmc1006407 · Cited by 245 · see citing works

Common Nonsynonymous Substitutions in SLCO1B1 Predispose to Statin Intolerance in Routinely Treated Individuals With Type 2 Diabetes: A Go-DARTS Study

Donnelly, L. A., Doney, A. S. F., Tavendale, R., Lang, C. C., Pearson, E. R., Colhoun, H. M., McCarthy, M. I., Hattersley, A. T., Morris, A. D., & Palmer, C. N. A. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.255 · Cited by 204 · see citing works

A randomized trial of Coenzyme Q10 in patients with confirmed statin myopathy

Taylor, B. A., Lorson, L., White, C. M., & Thompson, P. D. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.12.016 · Cited by 200 · see citing works

Statin therapy and plasma coenzyme Q10 concentrations—A systematic review and meta-analysis of placebo-controlled trials

Banach, M., Serban, C., Ursoniu, S., Rysz, J., Muntner, P., Toth, P. P., Jones, S. R., Rizzo, M., Glasser, S. P., Watts, G. F., et al. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.07.008 · Cited by 195 · see citing works

Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial

Visser, M. E., Wagener, G., Baker, B. F., Geary, R. S., Donovan, J. M., Beuers, U. H., Nederveen, A. J., Verheij, J., Trip, M. D., Basart, D. C. G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs023 · Cited by 191 · see citing works

Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience

Mampuya, W. M., Frid, D., Rocco, M., Huang, J., Brennan, D. M., Hazen, S. L., & Cho, L. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.06.004 · Cited by 173 · see citing works

Analysis of vitamin D levels in patients with and without statin-associated myalgia — A systematic review and meta-analysis of 7 studies with 2420 patients

Michalska, M., Sahebkar, A., Mikhailidis, D. P., Rysz, J., Muntner, P., Toth, P. P., Jones, S. R., Rizzo, M., Hovingh, G. K., Farnier, M., et al. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.10.118 · Cited by 171 · see citing works

Prevalence of Musculoskeletal Pain and Statin Use

Buettner, C., Davis, R. B., Leveille, S. G., Mittleman, M. A., & Mukamal, K. J. (2008) · Journal of General Internal Medicine · doi:10.1007/s11606-008-0636-7 · Cited by 158 · see citing works

Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance

Thompson, P. D., Rubino, J., Janik, M. J., MacDougall, D. E., McBride, S. J., Margulies, J. R., & Newton, R. S. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.03.003 · Cited by 158 · see citing works

Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial

Moriarty, P. M., Jacobson, T. A., Bruckert, E., Thompson, P. D., Guyton, J. R., Baccara-Dinet, M. T., & Gipe, D. (2014) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2014.09.007 · Cited by 154 · see citing works

Tolerability of Red Yeast Rice (2,400 mg Twice Daily) Versus Pravastatin (20 mg Twice Daily) in Patients With Previous Statin Intolerance

Halbert, S. C., French, B., Gordon, R. Y., Farrar, J. T., Schmitz, K., Morris, P. B., Thompson, P. D., Rader, D. J., & Becker, D. J. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.08.672 · Cited by 154 · see citing works

Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance

Thompson, P. D., MacDougall, D. E., Newton, R. S., Margulies, J. R., Hanselman, J. C., Orloff, D. G., McKenney, J. M., & Ballantyne, C. M. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.12.025 · Cited by 142 · see citing works

The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI): Revision for Clinical Use, Content Validation, and Inter-rater Reliability

Rosenson, R. S., Miller, K., Bayliss, M. S., Sanchez, R. J., Baccara‐Dinet, M. T., Chibedi-De-Roche, D., Taylor, B. A., Khan, I., Manvelian, G. Z., White, M. K., et al. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-017-6723-4 · Cited by 142 · see citing works

<i>N</i>-of-1 (Single-Patient) Trials for Statin-Related Myalgia

Joy, T. R., Monjed, A., Zou, G. Y., Hegele, R. A., McDonald, C. G., & Mahon, J. L. (2014) · Annals of Internal Medicine · doi:10.7326/m13-1921 · Cited by 130 · see citing works

Adherence to High-Intensity Statins Following a Myocardial Infarction Hospitalization Among Medicare Beneficiaries

Colantonio, L. D., Huang, L., Monda, K. L., Bittner, V., Șerban, M.-C., Taylor, B., Brown, T. M., Glasser, S. P., Muntner, P., & Rosenson, R. S. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.0911 · Cited by 128 · see citing works

The nocebo effect in the context of statin intolerance

Tobert, J. A., & Newman, C. B. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.05.002 · Cited by 125 · see citing works

Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study

McConnachie, A., Walker, A., Robertson, M., Marchbank, L., Peacock, J., Packard, C. J., Cobbe, S. M., & Ford, I. (2014) · European Heart Journal · doi:10.1093/eurheartj/eht232 · Cited by 104 · see citing works

Efficacy and Tolerability of Fluvastatin XL 80 mg Alone, Ezetimibe Alone, and the Combination of Fluvastatin XL 80 mg With Ezetimibe in Patients With a History of Muscle-Related Side Effects With Other Statins

Stein, E. A., Ballantyne, C. M., Windler, E., Sirnes, P. A., Sussekov, A., Yigit, Z., Seper, C., & Gimpelewicz, C. R. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.09.099 · Cited by 102 · see citing works

Statin intolerance because of myalgia, myositis, myopathy, or myonecrosis can in most cases be safely resolved by vitamin d supplementation

Glueck, C. J., Pandit, R., Kumar, A., Wang, P., Khayznikov, M., & Hemachrandra, K. (2015) · North American Journal of Medical Sciences · doi:10.4103/1947-2714.153919 · Cited by 102 · see citing works

Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia

Farnier, M. (1994) · Archives of Internal Medicine · doi:10.1001/archinte.154.4.441 · Cited by 87 · see citing works

Curcumin: an effective adjunct in patients with statin-associated muscle symptoms?

Sahebkar, A., Saboni, N., Pirro, M., & Banach, M. (2017) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12140 · Cited by 72 · see citing works

Effectiveness of Ezetimibe Alone or in Combination With Twice a Week Atorvastatin (10 mg) for Statin Intolerant High-Risk Patients

Athyros, V. G., Τζιόμαλος, Κ., Kakafika, A. I., Koumaras, H., Karagiannis, A. I., & Mikhailidis, D. P. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.09.096 · Cited by 71 · see citing works

Treating statin-intolerant patients

Arca, M., & Pigna (2011) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s11244 · Cited by 69 · see citing works

Identification and management of patients with statin-associated symptoms in clinical practice: A clinician survey

Hovingh, G. K., Gandra, S. R., McKendrick, J., Dent, R. E., Wieffer, H., Catapano, A. L., OH, P. I., Rosenson, R. S., & Stroes, E. S. G. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.12.015 · Cited by 62 · see citing works

Evaluation of skeletal muscle during calf exercise by 31-phosphorus magnetic resonance spectroscopy in patients on statin medications

Wu, J. S., Buettner, C., Smithline, H., Ngo, L. H., & Greenman, R. L. (2011) · Muscle &amp; Nerve · doi:10.1002/mus.21847 · Cited by 61 · see citing works

Statin Intolerance: the Clinician’s Perspective

Štulc, T., Češka, R., & Gotto, A. M. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-015-0552-3 · Cited by 59 · see citing works

Efficacy and Safety of Alternate-Day Versus Daily Dosing of Statins: a Systematic Review and Meta-Analysis

Awad, K., Mikhailidis, D. P., Toth, P. P., Jones, S. R., Moriarty, P. M., Lip, G. Y. H., Muntner, P., Catapano, A. L., Pencina, M. J., Rosenson, R. S., et al. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-017-6743-0 · Cited by 52 · see citing works

Colesevelam Hydrochloride-Ezetimibe Combination Lipid-Lowering Therapy in Patients with Diabetes or Metabolic Syndrome and a History of Statin Intolerance

Rivers, S. M., Kane, M. P., Busch, R. S., Bakst, G., & Hamilton, R. A. (2007) · Endocrine Practice · doi:10.4158/ep.13.1.11 · Cited by 50 · see citing works

Expert opinion: the therapeutic challenges faced by statin intolerance

Patel, J., Martin, S. S., & Banach, M. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1197202 · Cited by 50 · see citing works

Clinical and economic consequences of statin intolerance in the United States: Results from an integrated health system

Graham, J., Sanchez, R. J., Saseen, J. J., Mallya, U. G., Panaccio, M. P., & Evans, M. A. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.10.003 · Cited by 49 · see citing works

Usefulness of Nutraceuticals (Armolipid Plus) Versus Ezetimibe and Combination in Statin-Intolerant Patients With Dyslipidemia With Coronary Heart Disease

Marazzi, G., Pelliccia, F., Campolongo, G., Quattrino, S., Cacciotti, L., Volterrani, M., Gaudio, C., & Rosano, G. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.09.023 · Cited by 48 · see citing works

Efficacy of ezetimibe in patients with statin-resistant and statin-intolerant familial hyperlipidaemias

Wierzbicki, A. S., Doherty, E., Lumb, P. J., Chik, G., & Crook, M. A. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x28872 · Cited by 47 · see citing works

Symptomatic myositis-myalgia in hypercholesterolemic statin-treated patients with concurrent vitamin D deficiency leading to statin intolerance may reflect a reversible interaction between vitamin D deficiency and statins on skeletal muscle

Glueck, C. J., Abuchaibe, C., & Wang, P. (2011) · Medical Hypotheses · doi:10.1016/j.mehy.2011.07.007 · Cited by 33 · see citing works

Primary Care Physician Perspectives on Barriers to Statin Treatment

Tanner, R. M., Safford, M. M., Monda, K. L., Taylor, B., O’Beirne, R., Morris, M. S., Colantonio, L. D., Dent, R. E., Muntner, P., & Rosenson, R. S. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-017-6738-x · Cited by 30 · see citing works

Application of the Statin-Associated Muscle Symptoms-Clinical Index to a Randomized Trial on Statin Myopathy

Taylor, B. A., Sanchez, R. J., Jacobson, T. A., Chibedi-De-Roche, D., Manvelian, G. Z., Baccara‐Dinet, M. T., Khan, I., & Rosenson, R. S. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.07.767 · Cited by 29 · see citing works

Future Directions to Establish Lipoprotein(a) as a Treatment for Atherosclerotic Cardiovascular Disease

Stein, E. A., & Raal, F. J. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6654-5 · Cited by 28 · see citing works

Rechallenging Statin Therapy in Veterans With Statin-Induced Myopathy Post Vitamin D Replenishment

Kang, J. H., Nguyen, Q.-N., Mutka, J., & Le, Q. A. (2017) · Journal of Pharmacy Practice · doi:10.1177/0897190016674407 · Cited by 28 · see citing works

Somatic symptoms of anxiety and nonadherence to statin therapy

Korhonen, M. J., Pentti, J., Hartikainen, J. E. K., Mika Kivimaki, B., & Vahtera, J. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.04.003 · Cited by 26 · see citing works

Algorithms to Identify Statin Intolerance in Medicare Administrative Claim Data

Colantonio, L. D., Kent, S. T., Huang, L., Chen, L., Monda, K. L., Șerban, M.-C., Manthripragada, A. D., Kilgore, M. L., Rosenson, R. S., & Muntner, P. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6680-3 · Cited by 24 · see citing works

Additional therapy for cholesterol lowering in ezetimibe-treated, statin-intolerant patients in clinical practice: results from an internal audit of a university lipid clinic

Cicero, A. F. G., Morbini, M., Bove, M., D’Addato, S., Fogacci, F., Rosticci, M., & Borghi, C. (2016) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1190326 · Cited by 23 · see citing works

Identification and Management of Statin-Associated Symptoms in Clinical Practice: Extension of a Clinician Survey to 12 Further Countries

Rosenson, R. S., Gandra, S. R., McKendrick, J., Dent, R. E., Wieffer, H., Cheng, L., Catapano, A. L., OH, P. I., Hovingh, G. K., & Stroes, E. S. G. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-017-6727-0 · Cited by 21 · see citing works

Statin intolerance – a question of definition

Algharably, E. A. E., Filler, I., Rosenfeld, S., Grabowski, K., & Kreutz, R. H. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1238898 · Cited by 19 · see citing works

Development and Validation of Algorithms to Identify Statin Intolerance in a US Administrative Database

Schulman, K. L., Lamerato, L. E., Dalal, M. R., Sung, J., Jhaveri, M., Koren, A., Mallya, U. G., & Foody, J. M. (2016) · Value in Health · doi:10.1016/j.jval.2016.03.1858 · Cited by 14 · see citing works

A double-blind study of cefaclor and amoxycillin in home and hospital-acquired infections

Harrower, A. D. B. (1982) · Current Medical Research and Opinion · doi:10.1185/03007998209109748 · Cited by 11 · see citing works

PREVALENCE AND CORRELATES OF STATIN SIDE EFFECTS AND WILLINGNESS TO BE RE-CHALLENGED ON A STATIN: DATA FROM THE REASONS FOR GEOGRAPHIC AND RACIAL DIFFERENCES IN STROKE (REGARDS) STUDY

Tanner, R. M., Colantonio, L. D., Safford, M. M., Monda, K. L., Taylor, B., Muntner, P., & Rosenson, R. S. (2017) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(17)35087-8 · Cited by 2 · see citing works

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes

Knuuti, J., Wijns, W., Saraste, A., Capodanno, D., Barbato, E., Funck-Brentano, C., Prescott, E., Storey, R. F., Deaton, C., Cuisset, T., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz425 · Cited by 7,166 · see citing works

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

Collet, J.-P., Thiele, H., Barbato, E., Barthélémy, O., Bauersachs, J., Bhatt, D. L., Dendale, P., Dorobantu, M., Edvardsen, T., Folliguet, T., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa575 · Cited by 5,037 · see citing works

Statin Toxicity

Ward, N. C., Watts, G. F., & Eckel, R. H. (2019) · Circulation Research · doi:10.1161/circresaha.118.312782 · Cited by 772 · see citing works

Prevalence of statin intolerance: a meta-analysis

Bytyçi, I., Penson, P. E., Mikhailidis, D. P., Wong, N. D., Hernandez, A. V., Sahebkar, A., Thompson, P. D., Mazidi, M., Rysz, J., Pella, D., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac015 · Cited by 481 · see citing works

Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance

Laufs, U., Banach, M., Mancini, G. B. J., Gaudet, D., Bloedon, L. T., Sterling, L. R., Kelly, S., & Stroes, E. S. G. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.011662 · Cited by 432 · see citing works

Safety and efficacy of statin therapy

Adhyaru, B. B., & Jacobson, T. A. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0098-5 · Cited by 424 · see citing works

Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study

Ballantyne, C. M., Banach, M., Mancini, G. B. J., Lepor, N. E., Hanselman, J. C., Zhao, X., & Leiter, L. A. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.06.002 · Cited by 422 · see citing works

Lipid Management for the Prevention of Atherosclerotic Cardiovascular Disease

Michos, E. D., McEvoy, J. W., & Blumenthal, R. S. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1806939 · Cited by 350 · see citing works

Evinacumab in Patients with Refractory Hypercholesterolemia

Rosenson, R. S., Burgess, L. J., Ebenbichler, C. F., Baum, S. J., Stroes, E. S. G., Ali, S., Khilla, N., Hamlin, R., Pordy, R., Dong, Y., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2031049 · Cited by 302 · see citing works

Ten things to know about ten cardiovascular disease risk factors

Bays, H. E., Taub, P. R., Epstein, E., Michos, E. D., Ferraro, R. A., Bailey, A. L., Kelli, H. M., Ferdinand, K. C., Echols, M. R., Weintraub, H., et al. (2021) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2021.100149 · Cited by 274 · see citing works

The Role of Nutraceuticals in Statin Intolerant Patients

Banach, M., Patti, A. M., Giglio, R. V., Cicero, A. F. G., Atanasov, A. G., Bajraktari, G., Bruckert, E., Descamps, O., Djuric, D. M., Ezhov, M., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.040 · Cited by 272 · see citing works

The Evolving Future of PCSK9 Inhibitors

Rosenson, R. S., Hegele, R. A., Fazio, S., & Cannon, C. P. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.054 · Cited by 264 · see citing works

International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia

Watts, G. F., Gidding, S. S., Hegele, R. A., Raal, F. J., Sturm, A. C., Jones, L. K., Sarkies, M., Al‐Rasadi, K., Blom, D. J., Daccord, M., et al. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00892-0 · Cited by 257 · see citing works

Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials

Guedeney, P., Giustino, G., Sorrentino, S., Claessen, B. E., Camaj, A., Kalkman, D. N., Vogel, B., Sartori, S., De Rosa, S., Baber, U., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehz430 · Cited by 208 · see citing works

Sex- and Gender-Based Pharmacological Response to Drugs

Mauvais‐Jarvis, F., Berthold, H. K., Campesi, I., Carrero, J. J., Dhakal, S., Franconi, F., Gouni‐Berthold, I., Heiman, M. L., Kautzky‐Willer, A., Klein, S. L., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000206 · Cited by 194 · see citing works

Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia

Banach, M., Duell, P. B., Gotto, A. M., Laufs, U., Leiter, L. A., Mancini, G. B. J., Ray, K. K., Flaim, J., Ye, Z., & Catapano, A. L. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.2314 · Cited by 191 · see citing works

Management of Statin Intolerance in 2018: Still More Questions Than Answers

Toth, P. P., Patti, A. M., Giglio, R. V., Nikolić, D., Castellino, G., Rizzo, M., & Banach, M. (2018) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-017-0259-7 · Cited by 188 · see citing works

PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021

Banach, M., Burchardt, P., Chlebus, K., Dobrowolski, P., Dudek, D., Dyrbuś, K., Gąsior, M., Jankowski, P., Jozwiak, J. J., Kłosiewicz−Latoszek, L., et al. (2021) · Archives of Medical Science · doi:10.5114/aoms/141941 · Cited by 163 · see citing works

Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance

Nicholls, S., Lincoff, A. M., Bays, H. E., Cho, L., Grobbee, D. E., Kastelein, J. J., Libby, P., Moriarty, P. M., Plutzky, J., Ray, K. K., et al. (2021) · American Heart Journal · doi:10.1016/j.ahj.2020.10.060 · Cited by 136 · see citing works

Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care

Watts, G. F., Gidding, S. S., Mata, P., Pang, J., SULLIVAN, D. R., Yamashita, S., Raal, F. J., Santos, R. D., & Ray, K. K. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0325-8 · Cited by 138 · see citing works

Ten things to know about ten cardiovascular disease risk factors – 2022

Bays, H. E., Agarwala, A., German, C. A., Satish, P., Iluyomade, A., Dudum, R., Thakkar, A., Rifai, M. A., Mehta, A., Thobani, A., et al. (2022) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2022.100342 · Cited by 136 · see citing works

Assessment of trends in statin therapy for secondary prevention of atherosclerotic cardiovascular disease in US adults from 2007 to 2016

Yao, X., Shah, N. D., Gersh, B. J., Lopez-Jimenez, F., & Noseworthy, P. A. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.25505 · Cited by 117 · see citing works

Introducing the ‘Drucebo’ effect in statin therapy: a systematic review of studies comparing reported rates of statin‐associated muscle symptoms, under blinded and open‐label conditions

Penson, P. E., Mancini, G. B. J., Toth, P. P., Martin, S. S., Watts, G. F., Sahebkar, A., Mikhailidis, D. P., Banach, M., & on behalf of Lipid and Blood Pressure Meta‐Analysis Collaboration (LBPMC) Group & International Lipid Expert Panel (ILEP) (2018) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12344 · Cited by 110 · see citing works

Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials

Bays, H. E., Banach, M., Catapano, A. L., Duell, P. B., Gotto, A. M., Laufs, U., Leiter, L. A., Mancini, G. B. J., Ray, K. K., Bloedon, L. T., et al. (2020) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2020.08.009 · Cited by 103 · see citing works

Implication of liver enzymes on incident cardiovascular diseases and mortality: A nationwide population-based cohort study

Choi, K. M., Han, K., Park, S. H., Chung, H. S., Kim, N. H., Yoo, H. J., Seo, J. A., Kim, S. G., Kim, N. H., Baik, S. H., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-19700-8 · Cited by 93 · see citing works

Long-term statin persistence is poor among high-risk patients with dyslipidemia: a real-world administrative claims analysis

Toth, P. P., Granowitz, C. B., HULL, M. L., Anderson, A. J., & Philip, S. (2019) · Lipids in Health and Disease · doi:10.1186/s12944-019-1099-z · Cited by 89 · see citing works

Statin-Associated Muscle Disease: Advances in Diagnosis and Management

Taylor, B. A., & Thompson, P. D. (2018) · Neurotherapeutics · doi:10.1007/s13311-018-0670-z · Cited by 85 · see citing works

Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic

Katsiki, N., Banach, M., & Mikhailidis, D. P. (2020) · Archives of Medical Science · doi:10.5114/aoms.2020.94503 · Cited by 83 · see citing works

Step‐by‐step diagnosis and management of the nocebo/drucebo effect in statin‐associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP)

Penson, P. E., Bruckert, É., MARAIS, D. P., Reiner, Ž., Pirro, M., Sahebkar, A., Bajraktari, G., Mirrakhimov, E. M., Rizzo, M., Mikhailidis, D. P., et al. (2022) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12960 · Cited by 84 · see citing works

Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study

Rosenson, R. S., Daviglus, M. L., Handelsman, Y., Pozzilli, P., Bays, H., Monsalvo, M. L., Elliott-Davey, M., Somaratne, R., & Reaven, P. (2019) · Diabetologia · doi:10.1007/s00125-019-4856-7 · Cited by 73 · see citing works

Role of genetics in the prediction of statin-associated muscle symptoms and optimization of statin use and adherence

Brunham, L. R., Baker, S. K., Mammen, A. L., Mancini, G. B. J., & Rosenson, R. S. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy119 · Cited by 71 · see citing works

Surface stabilized atorvastatin nanocrystals with improved bioavailability, safety and antihyperlipidemic potential

Sharma, M., & Mehta, I. (2019) · Scientific Reports · doi:10.1038/s41598-019-52645-0 · Cited by 70 · see citing works

Statins for Primary Prevention in Older Adults—Moving Toward Evidence‐Based Decision‐Making

Singh, S., Zieman, S. J., Go, A. S., Fortmann, S. P., WENGER, N. K., Fleg, J. L., Radziszewska, B., Stone, N. J., Zoungas, S., & Gurwitz, J. H. (2018) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15449 · Cited by 67 · see citing works

Brief recommendations on the management of adult patients with familial hypercholesterolemia during the COVID-19 pandemic

Banach, M., Penson, P. E., Fras, Z., Vrablı́k, M., Pella, D., Reiner, Ž., Nabavi, S. M., Sahebkar, A., Kayıkçıoğlu, M., & Daccord, M. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104891 · Cited by 67 · see citing works

A comprehensive review on the lipid and pleiotropic effects of pitavastatin

Sahebkar, A., Kiaie, N., Gorabi, A. M., Mannarino, M. R., Bianconi, V., Jamialahmadi, T., Pirro, M., & Banach, M. (2021) · Progress in Lipid Research · doi:10.1016/j.plipres.2021.101127 · Cited by 68 · see citing works

Evolocumab in HIV-Infected Patients With Dyslipidemia

Boccara, F., Kumar, P. N., Caramelli, B., Calmy, A., López, J. A. G., Bray, S. L., Cyrille, M., Rosenson, R. S., Baker, D. A., Bloch, M., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.03.025 · Cited by 63 · see citing works

An overview of statin-induced myopathy and perspectives for the future

Nikolić, D., Banach, M., Chianetta, R., Luzzu, L. M., Stoian, A. P., Diaconu, C. C., Citarrella, R., Montalto, G., & Rizzo, M. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1747431 · Cited by 65 · see citing works

Cholesterol-Lowering Agents

Rosenson, R. S., Hegele, R. A., & Köenig, W. (2019) · Circulation Research · doi:10.1161/circresaha.118.313238 · Cited by 61 · see citing works

Appropriateness of statin prescription in the elderly

Ruscica, M., Macchi, C., Pavanello, C., Corsini, A., Sahebkar, A., & Sirtori, C. R. (2018) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.12.011 · Cited by 60 · see citing works

Hypercholesterolaemia – practical information for non-specialists

Soran, H., Adam, S., Mohamad, J. B., Ho, J. H., Schofield, J. D., Kwok, S., Siahmansur, T. J., Liu, Y., Syed, A. A., Dhage, S. S., et al. (2018) · Archives of Medical Science · doi:10.5114/aoms.2018.72238 · Cited by 57 · see citing works

ETC-1002 (Bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials

Ruscica, M., Banach, M., Sahebkar, A., Corsini, A., & Sirtori, C. R. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1583209 · Cited by 55 · see citing works

What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcome trials: ODYSSEY and FOURIER?

Banach, M., & Penson, P. E. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy301 · Cited by 54 · see citing works

Coronavirus and Cardiometabolic Syndrome

Mechanick, J. I., Rosenson, R. S., Pinney, S., MANCINI, D. M., Narula, J., & Fuster, V. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.07.069 · Cited by 50 · see citing works

Safety and tolerability of injectable lipid-lowering drugs: an update of clinical data

Strilchuk, L. M., Fogacci, F., & Cicero, A. F. G. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1620730 · Cited by 48 · see citing works

The role of red yeast rice (RYR) supplementation in plasma cholesterol control: A review and expert opinion

Banach, M., Bruckert, É., Descamps, O. S., Ellegård, L., Владиславович, Е. М., Föger, B., Fras, Z., Kovanen, P. T., Latkovskis, G., März, W., et al. (2019) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2019.08.023 · Cited by 46 · see citing works

Familial Hypercholesterolaemia in 2020: A Leading Tier 1 Genomic Application

Pang, J., SULLIVAN, D. R., Brett, T., Kostner, K., Hare, D. L., & Watts, G. F. (2019) · Heart Lung and Circulation · doi:10.1016/j.hlc.2019.12.002 · Cited by 45 · see citing works

Lipid-Lowering Effects of Medium-Chain Triglyceride-Enriched Coconut Oil in Combination with Licorice Extracts in Experimental Hyperlipidemic Mice

Lee, E., Oh, H., Kang, B. G., Kang, M., Kim, D. Y., Kim, Y., Lee, J. Y., Ji, J. G., Lim, S. S., & Kang, Y. (2018) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.8b04080 · Cited by 44 · see citing works

Statin-Induced Myopathy: Translational Studies from Preclinical to Clinical Evidence

Camerino, G. M., Tarantino, N., Canfora, I., Bellis, M. D., Musumeci, O., & Pierno, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042070 · Cited by 46 · see citing works

Low-Density Lipoprotein Cholesterol-Lowering Drugs: A Narrative Review

Ferri, N., Ruscica, M., Fazio, S., & Corsini, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13040943 · Cited by 41 · see citing works

Statin Intolerance

Banach, M., & Mikhailidis, D. P. (2018) · Cardiology Clinics · doi:10.1016/j.ccl.2017.12.004 · Cited by 42 · see citing works

The potential role of statins in preeclampsia and dyslipidemia during gestation: a narrative review

Maierean, S. M., Mikhailidis, D. P., Toth, P. P., Grzesiak, M., Mazidi, M., Maciejewski, M., & Banach, M. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1465927 · Cited by 44 · see citing works

Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials

Laufs, U., Ballantyne, C. M., Banach, M., Bays, H. E., Catapano, A. L., Duell, P. B., Goldberg, A. C., Gotto, A. M., Leiter, L. A., Ray, K. K., et al. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.03.001 · Cited by 42 · see citing works

Muscle and statins: from toxicity to the nocebo effect

Pedro‐Botet, J., Climent, E., & Benaiges, D. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1615053 · Cited by 40 · see citing works

Effect of bergamot on lipid profile in humans: A systematic review

Lamíquiz-Moneo, I., Giné-González, J., Alisente, S., Bea, A. M., Pérez‐Calahorra, S., Marco-Benedí, V., Baila-Rueda, L., Jarauta, E., Cenarro, A., Civeira, F., et al. (2019) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2019.1677554 · Cited by 40 · see citing works

Characteristics of lipid profile and effectiveness of management of dyslipidaemia in patients with acute coronary syndromes – Data from the TERCET registry with 19,287 patients

Dyrbuś, K., Gąsior, M., Desperak, P., Nowak, J. U., Osadnik, T., & Banach, M. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.12.002 · Cited by 39 · see citing works

Effect of Evolocumab on Non‐High‐Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies

Toth, P. P., Jones, S. R., Monsalvo, M. L., Elliott‐Davey, M., López, J. A. G., & Banach, M. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.014129 · Cited by 36 · see citing works

2021 PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on the diagnosis and therapy of lipid disorders in Poland

Banach, M., Burchardt, P., Chlebus, K., Dobrowolski, P., Dudek, D., Dyrbuś, K., Gąsior, M., Jankowski, P., Jozwiak, J. J., Kłosiewicz−Latoszek, L., et al. (2021) · Diagnostyka Laboratoryjna · doi:10.5604/01.3001.0015.4805 · Cited by 36 · see citing works

Nutraceuticals in the management of patients with statin‐associated muscle symptoms, with a note on real‐world experience

Ward, N. C., Pang, J., Ryan, J. D. M., & Watts, G. F. (2018) · Clinical Cardiology · doi:10.1002/clc.22862 · Cited by 36 · see citing works

Neuromuscular Complications of Statin Therapy

Crisan, E., & Patil, V. K. (2020) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-020-01064-0 · Cited by 36 · see citing works

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes

(2020) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2020.05.011 · Cited by 36 · see citing works

Moving Targets

Larsen, L. E., Stoekenbroek, R. M., Kastelein, J. J. P., & Holleboom, A. G. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.312028 · Cited by 34 · see citing works

Coenzyme Q10 as Treatment for Statin-Associated Muscle Symptoms—A Good Idea, but…

Zaleski, A. L., Taylor, B. A., & Thompson, P. D. (2018) · Advances in Nutrition · doi:10.1093/advances/nmy010 · Cited by 32 · see citing works

Prosarcopenic Effects of Statins May Limit Their Effectiveness in Patients with Heart Failure

Bielecka-Dabrowa, A. M., Fabiś, J., Mikhailidis, D. P., von Haehling, S., Sahebkar, A., Rysz, J., & Banach, M. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.02.003 · Cited by 30 · see citing works

Statins: Complex outcomes but increasingly helpful treatment options for patients

Mohammadkhani, N., Gharbi, S., Rajani, H. F., Farzaneh, A., Mahjoob, G., Hoseinsalari, A., & Korsching, E. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172704 · Cited by 32 · see citing works

Switching, Persistence and Adherence to Statin Therapy: a Retrospective Cohort Study Using the Australian National Pharmacy Data

Talic, S., Marquina, C., Ofori‐Asenso, R., Petrova, M., Liew, D., Owen, A. J., Lybrand, S., Thomson, D., Ilomäki, J., Zomer, E., et al. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07199-7 · Cited by 32 · see citing works

Ginsenosides regulation of lysophosphatidylcholine profiles underlies the mechanism of Shengmai Yin in attenuating atherosclerosis

Wang, Y., Zhu, J., Zhu, J., Ding, C., Xu, W., Hao, H., Zhang, J., Wang, G., & Cao, L. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.114223 · Cited by 31 · see citing works

Pharmacokinetics and pharmacodynamics of HTD1801 (berberine ursodeoxycholate, BUDCA) in patients with hyperlipidemia

Bisceglie, A. M. D., Watts, G. F., Lavin, P. T., Yu, M., Bai, R., & Liu, L. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01406-4 · Cited by 30 · see citing works

How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors

Cybulska, B., Kłosiewicz−Latoszek, L., Penson, P. E., Nabavi, S. M., Lavie, C. J., & Banach, M. (2020) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2020.12.008 · Cited by 30 · see citing works

Expert opinion on the integration of combination therapy into the treatment algorithm for the management of dyslipidaemia: the integration of ezetimibe and bempedoic acid may enhance goal attainment

Parhofer, K. G., Aguíar, C., Banach, M., Drexel, H., Gouni‐Berthold, I., de Isla, L. P., Rietzschel, E. R., Zambon, A., & Ray, K. K. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf007 · Cited by 31 · see citing works

Suggested clinical approach for the diagnosis and management of ‘statin intolerance’ with an emphasis on muscle‐related side‐effects

Sivashanmugarajah, A. S., Fulcher, J., SULLIVAN, D. R., Elam, M. B., Jenkins, A. J., & KEECH, A. C. (2019) · Internal Medicine Journal · doi:10.1111/imj.14429 · Cited by 26 · see citing works

Guía ESC 2020 sobre el diagnóstico y tratamiento del síndrome coronario agudo sin elevación del segmento ST

Collet, J., Thiele, H., Barbato, E., Barthélémy, O., Bauersachs, J. K., Bhatt, D. L., Dendale, P., Dorobanţu, M., Edvardsen, T., Folliguet, T. A., et al. (2021) · Revista Española de Cardiología · doi:10.1016/j.recesp.2020.12.024 · Cited by 28 · see citing works

Statin therapy in athletes and patients performing regular intense exercise – Position paper from the International Lipid Expert Panel (ILEP)

Katsiki, N., Mikhailidis, D. P., Bajraktari, G., Miserez, A. R., Cicero, A. F. G., Bruckert, É., Șerban, M.-C., Mirrakhimov, E. M., Alnouri, F., Reiner, Ž., et al. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104719 · Cited by 27 · see citing works

High-dose atorvastatin therapy progressively decreases skeletal muscle mitochondrial respiratory capacity in humans

RYAN, T. E., Torres, M. J., Lin, C., Clark, A. H., Brophy, P. M., Smith, C. A. S., Smith, C. D., Morris, E. M., Thyfault, J. P., & Neufer, P. D. (2024) · JCI Insight · doi:10.1172/jci.insight.174125 · Cited by 26 · see citing works

Evaluation of dyslipidaemia and the impact of hypolipidemic therapy on prognosis in high and very high risk patients through the Hyperlipidaemia Therapy in tERtiary Cardiological cEnTer (TERCET) Registry

Dyrbuś, K., Osadnik, T., Desperak, P., Desperak, A., Gąsior, M., & Banach, M. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.12.015 · Cited by 26 · see citing works

Willingness to be Reinitiated on a Statin (from the REasons for Geographic and Racial Differences in Stroke Study)

Mefford, M. T., Tajeu, G. S., Tanner, R. M., Colantonio, L. D., Monda, K. L., Dent, R. E., Farkouh, M. E., Rosenson, R. S., Safford, M. M., & Muntner, P. (2018) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2018.05.016 · Cited by 24 · see citing works

The effect of PCSK9 inhibitors on brain stroke prevention: A systematic review and meta-analysis

Qin, J., Liu, L., Su, X. D., Wang, B. B., Fu, B. S., Cui, J., & Liu, X. Y. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.03.026 · Cited by 25 · see citing works

Treatment adherence and effect of concurrent statin intensity on the efficacy and safety of alirocumab in a real-life setting: results from ODYSSEY APPRISE

Banach, M., Lopez-Sendon, J. L., Averna, M. R., Cariou, B., Loy, M., Manvelian, G. Z., Batsu, I., Poulouin, Y., & Gaudet, D. (2021) · Archives of Medical Science · doi:10.5114/aoms/143476 · Cited by 24 · see citing works

Statin therapy in chronic viral hepatitis: a systematic review and meta-analysis of nine studies with 195,602 participants

Vahedian‐Azimi, A., Shojaie, S., Banach, M., Heidari‐Beni, F., Cicero, A. F. G., Khoshfetrat, M., Jamialahmadi, T., & Sahebkar, A. (2021) · Annals of Medicine · doi:10.1080/07853890.2021.1956686 · Cited by 24 · see citing works

Persistent Safety and Efficacy of Evolocumab in Patients with Statin Intolerance: a Subset Analysis of the OSLER Open-Label Extension Studies

Cho, L., Dent, R. E., Stroes, E. S. G., Stein, E. A., SULLIVAN, D. R., Ruzza, A., Flower, A., Somaratne, R. M., & Rosenson, R. S. (2018) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-018-6817-7 · Cited by 23 · see citing works

Naringin reduces body weight, plasma lipids and increases adiponectin levels in patients with dyslipidemia

Barajas-Vega, J. L., Orozco, A. K. R., Hernandez-Molina, D., Ávila-González, A. E., García-Cobián, T. A., Arellano, E. D. R., & Ramírez-Lizardo, E. J. (2020) · International Journal for Vitamin and Nutrition Research · doi:10.1024/0300-9831/a000658 · Cited by 23 · see citing works

Efficacy of functional foods mixture in improving hypercholesterolemia, inflammatory and endothelial dysfunction biomarkers-induced by high cholesterol diet

Al-Muzafar, H. M., & Amin, K. A. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0585-4 · Cited by 22 · see citing works

Overview the effect of statin therapy on dementia risk, cognitive changes and its pathologic change: a systematic review and meta-analysis

Zhu, X., Dai, W.-Z., & Ma, T. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.06.43 · Cited by 21 · see citing works

Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease

Cannon, C. P., Sanchez, R. J., Klimchak, A. C., Khan, I., Sasiela, W. J., Reynolds, M. R., & Rosenson, R. S. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.01.028 · Cited by 19 · see citing works

Quantitative evaluation of statin effectiveness versus intolerance and strategies for management of intolerance

Soran, H., France, M. W., Adam, S., Iqbal, Z., Ho, J. H., & Durrington, P. N. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.06.023 · Cited by 18 · see citing works

Statin intolerance management: a systematic review

Meza-Contreras, A., Wenczenovicz, C., Ruiz-Arellanos, K., Kinzelman-Vesely, E. A., Mogollon, R. J., & Montori, V. M. (2022) · Endocrine · doi:10.1007/s12020-022-03263-w · Cited by 18 · see citing works

Significant progress in improving Atorvastatin dissolution rate: Physicochemical characterization and stability assessment of self-dispersible Atorvastatin/Tween 80® nanocrystals formulated through wet milling and freeze-drying

Rossetti, A., Real, D. A., Barrientos, B. A., Allemandi, D. A., Paredes, A. J., Real, J. P., & Palma, S. D. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123720 · Cited by 18 · see citing works

Drucebo effect – the challenge we should all definitely face!

Banach, M., & Penson, P. E. (2021) · Archives of Medical Science · doi:10.5114/aoms/132304 · Cited by 18 · see citing works

Efficacy of Statin Therapy in Patients with Hospital Admission for COVID-19

Choi, D., Chen, Q., Goonewardena, S. N., Pacheco, H., Mejia, P., Smith, R. L., & Rosenson, R. S. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07263-2 · Cited by 17 · see citing works

Regulation of lactate production through p53/β-enolase axis contributes to statin-associated muscle symptoms

Huang, J., Du, J., Lin, W., Long, Z., Zhang, N., Huang, X., Xie, Y., Liu, L., & Ma, W. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.06.003 · Cited by 15 · see citing works

Ten things to know about ten cardiovascular disease risk factors (“ASPC Top Ten – 2020”)

Bays, H. E. (2020) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2020.100003 · Cited by 19 · see citing works

Statins and Cardiomyocyte Metabolism, Friend or Foe?

Somers, T., Siddiqi, S., Morshuis, W. J., Rüssel, F. G. M., & Schirris, T. J. J. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10100417 · Cited by 16 · see citing works

Association Between Adherence to Statins, Illness Perception, Treatment Satisfaction, and Quality of Life among Lebanese patients

Haddad, C., Hallit, S. R., Salhab, M., Hajj, A., Sarkis, A., Ayoub, E. N., Jabbour, K., & Khabbaz, L. R. (2018) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248418769635 · Cited by 17 · see citing works

Efficacy and safety of a combination of red yeast rice and olive extract in hypercholesterolemic patients with and without statin-associated myalgia

Muhindo, C. T., Ahn, S. A., Rousseau, M. F., Dierckxsens, Y., & Hermans, M. P. (2017) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2017.10.014 · Cited by 16 · see citing works

Comparative Effectiveness of Inclisiran 100, 300, and 500 mg in a Population with Hyperlipidemia: A Network Meta-Analysis of Randomized Controlled Trials

Wang, Y., Wang, J., & Wang, S. (2018) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-0270-7 · Cited by 16 · see citing works

Sex disparity in the management and outcomes of dyslipidemia of diabetic patients in the Arabian Gulf: findings from the CEPHEUS study

Al-Zakwani, I. S., Al-Mahruqi, F., Al‐Rasadi, K., Shehab, A. M., Almahmeed, W. A., Arafah, M., Al-Hinai, A. T., Tamimi, O. A., Alawadhi, M., & Santos, R. D. (2018) · Lipids in Health and Disease · doi:10.1186/s12944-018-0667-y · Cited by 12 · see citing works

Validation of a clinically-relevant rodent model of statin-associated muscle symptoms for use in pharmacological studies

Irwin, J. C., Fenning, A. S., Ryan, K., & Vella, R. K. (2018) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2018.09.040 · Cited by 12 · see citing works

Pharmacotherapy of the Lipid-Lowering Drugs: Update on Efficacy and Risk

Pierno, S., & Musumeci, O. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24020996 · Cited by 11 · see citing works

Predictors of Statin Intolerance in Patients With a New Diagnosis of Atherosclerotic Cardiovascular Disease Within a Large Integrated Health Care Institution: The IMPRES Study

Bair, T. L., May, H. T., Knowlton, K. U., Anderson, J. L., LAPPE, D. L., & Muhlestein, J. B. (2020) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000808 · Cited by 11 · see citing works

Combination effect naringin and pravastatin in lipid profile and glucose in obese rats

Orozco, A. K. R., Ávila-González, A. E., Rodríguez-Razón, C. M., García-Cobián, T. A., Pérez-Guerrero, E. E., García‐Iglesias, T., & Arellano, E. D. R. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.11.044 · Cited by 11 · see citing works

Genetic Variation in Statin Intolerance and a Possible Protective Role for UGT1A1

Willrich, M. A. V., Kaleta, E. J., Bryant, S. C., Spears, G. M., Train, L. J., Peterson, S. E., Lennon, V. A., Kopecky, S. L., & Baudhuin, L. M. (2017) · Pharmacogenomics · doi:10.2217/pgs-2017-0146 · Cited by 11 · see citing works

Diagnosis and Management of Statin Intolerance

Rodrigo Alonso, K., Cuevas, A. M., & Cafferata, A. (2019) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17030 · Cited by 109 · see citing works

Statin intolerance: an updated, narrative review mainly focusing on muscle adverse effects

Li, J., Liu, H.-H., Wu, N., Yeo, K. K., Tan, K. C. B., Ako, J., Krittayaphong, R., Tan, R., Aylward, P. E., Baek, S. H., et al. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1802426 · Cited by 19 · see citing works

Statin Intolerance: the Clinician’s Perspective

Štulc, T., Češka, R., & Gotto, A. M. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-015-0552-3 · Cited by 59 · see citing works

[Practical approach to statin intolerance].

Štulc, T., Beránková, Š., & Češka, R. (2015) · PubMed

Advances in the management of statin myopathy

Gallo, A., Perregaux, J., & Bruckert, É. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000595 · Cited by 6 · see citing works